With an estimated duration of response rate of 90.6% at six months and 66.5% at nine months in the agent’s clinical trials, in October 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four previous lines of therapy.
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education